RxDoctor Payments DataLook up a doctor →

Matthew German, MD

Infectious Disease · Chesterfield, MONPI 1073628871

Payments from drug & device makers

$16,085in general payments, 2019–2025

Across 777 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$4K
  • Gilead$2K
  • AbbVie$2K
  • Merck$1K
  • Johnson & Johnson$943
  • Amgen$392
  • plus $6K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Viiv Healthcare Company183$4,104
Gilead113$2,274
AbbVie(2 entities)71$1,738
Merck62$1,084
Johnson & Johnson(2 entities)54$943
Amgen(2 entities)19$392
Insmed, Inc.20$386
Aimmune Therapeutics, Inc.18$342
Napo Pharmaceuticals Inc20$329
Theratechnologies Inc.13$293
Pfizer17$287
UCB, Inc.13$284
Shionogi Inc13$281
Organogenesis Inc.12$230
EMD Serono, Inc.11$213
Bayer11$203
Abbott2$196
AstraZeneca(2 entities)9$182
Otsuka America Pharmaceutical, Inc.10$176
Cumberland Pharmaceuticals, Inc.13$175
Paratek Pharmaceuticals, Inc.9$174
Janssen Scientific Affairs, LLC2$139
Lilly USA, LLC8$115
Calliditas Therapeutics US Inc.5$108
Janssen Products, LP1$100
Fresenius USA Marketing, Inc.5$88
Astellas Pharma US Inc4$87
Vifor Pharma, Inc.4$74
Tetraphase Pharmaceuticals, Inc.4$69
Sanofi Pasteur Inc.4$65
Melinta Therapeutics, LLC4$62
Mayne Pharma Commercial LLC4$62
E.r. Squibb & Sons, L.L.C.3$55
Esperion Therapeutics, Inc.2$52
Mallinckrodt Hospital Products Inc.2$52
Pharmacosmos Therapeutics Inc.2$50
Qiagen, LLC1$48
Boehringer Ingelheim2$45
Scpharmaceuticals Inc.2$43
Aurinia Pharma U.S., Inc.2$42
Vantive US Healthcare LLC1$38
GSK2$36
Novo Nordisk2$35
Ferring Pharmaceuticals Inc.2$31
La Jolla Pharmaceutical Company1$28
Travere Therapeutics, Inc.1$25
Mylan Institutional Inc.1$23
Octapharma USA, Inc.1$22
Ardelyx, Inc.1$22
Novartis1$20
Genentech USA, Inc.1$20
Sandoz1$20
Nestle Healthcare Nutrition Inc.1$19
VBI Vaccine (delaware) Inc.1$18
Apellis Pharmaceuticals, Inc.1$18
Alnylam Pharmaceuticals Inc.1$17
Otsuka Pharmaceutical Development & Commercialization, Inc.1$15
OPKO Pharmaceuticals, LLC1$14
Nabriva Therapeutics, PLC1$12
Aytu Biopharma, Inc.1$11

How this compares

$16,085 in reported general payments places this provider in the 85th percentile of 177 infectious disease providers in Missouri.

See all infectious disease providers in Missouri →

Medicare billing

Part B allowed, 2024
$92,253
Medicare patients
219
Services billed
876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Chesterfield

See the full list for Missouri →

Where these figures come from

Is this you, or does something look wrong? →